December 20, 2004 - 8:32 a.m.
Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines
Printer Friendly Version 
December 03, 2004 - 4:32 p.m.
Gilead Sciences to Present at the Harris Nesbitt 4th Annual Investor Conference on Wednesday, December 8th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 30, 2004 - 4:32 p.m.
Gilead Sciences to Present at the Lazard 1st Annual Life Sciences Conference on Wednesday, December 1st; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 29, 2004 - 8:32 a.m.
Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds
Printer Friendly Version 
November 22, 2004 - 8:32 a.m.
Gilead Sciences Announces Completion of Redemption of 2% Convertible Senior Notes
Printer Friendly Version 
November 19, 2004 - 4:32 p.m.
Gilead Sciences to Present at the Punk, Ziegel & Company's Investor Symposium on Monday, November 22nd; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 18, 2004 - 8:22 a.m.
European CHMP Gives Positive Opinion on Gilead's Truvada as Part of Combination HIV Therapy
Printer Friendly Version 
November 15, 2004 - 4:32 p.m.
Gilead Sciences to Present at the Credit Suisse First Boston Annual Healthcare Conference on Thursday, November 18th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 02, 2004 - 8:02 a.m.
Gilead Announces Long-Term Safety and Efficacy Data, Through 144 Weeks, for Hepsera in Patients With Chronic Hepatitis B
Printer Friendly Version 
October 31, 2004 - 4:32 p.m.
Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC
Printer Friendly Version 
October 21, 2004 - 4:08 p.m.
Gilead Discontinues Development of GS 9005 and GS 7340; Company Continues Commitment to Research Efforts in HIV
Printer Friendly Version 
October 21, 2004 - 4:01 p.m.
Gilead Sciences Announces Third Quarter 2004 Financial Results
Printer Friendly Version 
October 14, 2004 - 8:33 a.m.
Gilead Sciences to Release Third Quarter 2004 Financial Results on Thursday, October 21, 2004; Conference Call and Webcast to Follow
Printer Friendly Version 
October 06, 2004 - 8:31 a.m.
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
Printer Friendly Version 
September 30, 2004 - 8:32 a.m.
Gilead and Genelabs Announce Research Collaboration and License Agreement for the Development of Genelabs' Novel Hepatitis C Compounds
Printer Friendly Version 
September 29, 2004 - 7:03 p.m.
CORRECTING and REPLACING Gilead Sciences Announces Acceptance of Study 934 Late Breaker Abstract at 44th Annual ICAAC in Washington, DC
Printer Friendly Version 
September 24, 2004 - 5:52 p.m.
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 27th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
September 14, 2004 - 4:32 p.m.
Kevin Young Joins Gilead Sciences as Executive Vice President, Commercial Operations
Printer Friendly Version 
September 03, 2004 - 8:31 a.m.
Gilead Sciences to Present at the BioCentury and Thomson Financial Newsmakers in the Biotech Industry Conference on Thursday, September 9th
Printer Friendly Version 
September 03, 2004 - 8:31 a.m.
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference on Wednesday, September 8th
Printer Friendly Version 
August 26, 2004 - 8:32 a.m.
Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV
Printer Friendly Version 
August 18, 2004 - 8:32 a.m.
Gilead Expands Initiatives Providing Access to New HIV Therapy Truvada in United States and Abroad
Printer Friendly Version 
August 17, 2004 - 8:32 a.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
August 02, 2004 - 1:38 p.m.
U.S. FDA Approves Gilead's Truvada, a One-Tablet, Once-a-Day Fixed-Dose Co-Formulation of Viread and Emtriva as Part of HIV Combination Therapy
Printer Friendly Version 
July 29, 2004 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2004 Financial Results
Printer Friendly Version 
July 28, 2004 - 4:27 p.m.
Gilead Board of Directors Approves Two-for-One Stock Split
Printer Friendly Version 
July 22, 2004 - 4:32 p.m.
Gilead Sciences to Release Second Quarter 2004 Financial Results on Thursday, July 29, 2004; Conference Call and Webcast to Follow
Printer Friendly Version 
July 12, 2004 - 8:32 a.m.
Gilead Signs Inventory Management Agreements with the Three Major U.S. Wholesalers
Printer Friendly Version 
July 10, 2004 - 11:02 p.m.
Pivotal Studies of Gilead's Viread and Emtriva Published in Special International Aids Conference Issue of Journal of the American Medical Association
Printer Friendly Version 
July 09, 2004 - 8:31 a.m.
Gilead Reduces Price of Viread in the Developing World by 37 Percent; Anti-HIV Medication Available to 68 Resource-Limited Countries Through the Gilead Access Program
Printer Friendly Version 
June 23, 2004 - 7:04 p.m.
Gilead Sciences to be Added to S&P 500 Index
Printer Friendly Version 
June 07, 2004 - 4:32 p.m.
Gilead Sciences to Present at the 25th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
May 19, 2004 - 3:37 p.m.
CORRECTING and REPLACING Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st
Printer Friendly Version 
May 18, 2004 - 5:02 p.m.
Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
May 16, 2004 - 11:02 a.m.
Bristol-Myers Squibb, Gilead Sciences and Merck & Co., Inc. Announce Plans to Develop Fixed-Dose Combination of Three HIV Medicines
Printer Friendly Version 
May 03, 2004 - 9:04 a.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
April 27, 2004 - 9:03 a.m.
Gilead Sciences Announces New Commercial Structure and Changes to Senior Management Team; Expansion and Reorganization of Commercial Group to Support Anticipated Growth
Printer Friendly Version 
April 22, 2004 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2004 Financial Results; Total Revenues of $309 Million, Up 87 Percent over First Quarter 2003
Printer Friendly Version 
April 16, 2004 - 4:32 p.m.
Gilead Sciences to Release First Quarter 2004 Financial Results on Thursday, April 22, 2004; Conference Call and Webcast to Follow
Printer Friendly Version 
April 15, 2004 - 4:32 p.m.
New Data Support Hepsera's Long-Term Efficacy against Chronic Hepatitis B
Printer Friendly Version 
March 25, 2004 - 8:32 a.m.
Nicholas G. Moore Joins Gilead Sciences Board of Directors
Printer Friendly Version 
March 15, 2004 - 8:31 a.m.
Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva
Printer Friendly Version 
March 08, 2004 - 8:33 a.m.
Gilead Sciences to Present at the 24th Annual SG Cowen Healthcare Conference on Tuesday, March 9th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
March 04, 2004 - 2:02 p.m.
Gilead Sciences to Present at the 7th Annual Lehman Brothers Global Healthcare Conference on Friday, March 5th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
February 23, 2004 - 4:32 p.m.
Gilead Sciences to Present at 2004 BIO CEO & Investor Conference; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
February 04, 2004 - 7:48 a.m.
Gilead Announces Data from Landmark Three-Year Clinical Trial of Viread; 144-Week Data Highlight Viread Efficacy, Safety and Side Effect Profile
Printer Friendly Version 
January 29, 2004 - 4:03 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2003 Financial Results
Printer Friendly Version 
January 28, 2004 - 7:47 a.m.
Gilead, Emory University and the University of Georgia Research Foundation End Licensing Agreement for Amdoxovir, Investigational Agent for HIV
Printer Friendly Version 
January 23, 2004 - 4:32 p.m.
Gilead Sciences to Release Fourth Quarter and Year-End 2003 Financial Results on Thursday, January 29, 2004; Conference Call and Webcast to Follow
Printer Friendly Version 
January 12, 2004 - 8:11 a.m.
Gilead Files Investigational New Drug Application for Its Novel Protease Inhibitor; Anti-HIV Drug Developed Using Gilead's Proprietary Prodrug Technology
Printer Friendly Version 
January 09, 2004 - 4:03 p.m.
Gilead Sciences to Present at the 22nd Annual JPMorgan Healthcare Conference on Monday, January 12th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
NASDAQ (US Dollar)
$75.57
 Stock is Up 1.23 (1.65%)
Data as of 12/15/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote